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The zebrafish is rapidly emerging as a promising alternative in vivo model for the detection 
of drug-induced cardiovascular effects. Despite its increasing popularity, the ability of 
this model to inform the drug development process is often limited by the uncertainties 
around the quantitative relevance of zebrafish responses compared with nonclinical 
mammalian species and ultimately humans. In this test of concept study, we provide a 
comparative quantitative analysis of the in vivo cardiovascular responses of zebrafish, rat, 
dog, and human to three model compounds (propranolol, losartan, and captopril), which 
act as modulators of two key systems (beta-adrenergic and renin–angiotensin systems) 
involved in the regulation of cardiovascular functions. We used in vivo imaging techniques 
to generate novel experimental data of drug-mediated cardiovascular effects in zebrafish 
larvae. These data were combined with a database of interspecies mammalian responses 
(i.e., heart rate, blood flow, vessel diameter, and stroke volume) extracted from the literature 
to perform a meta-analysis of effect size and direction across multiple species. In spite of 
the high heterogeneity of study design parameters, our analysis highlighted that zebrafish 
and human responses were largely comparable in >80% of drug/endpoint combinations. 
However, it also revealed a high intraspecies variability, which, in some cases, prevented 
a conclusive interpretation of the drug-induced effect. Despite the shortcomings of our 
study, the meta-analysis approach, combined with a suitable data visualization strategy, 
enabled us to observe patterns of response that would likely remain undetected with 
more traditional methods of qualitative comparative analysis. We propose that expanding 
this approach to larger datasets encompassing multiple drugs and modes of action would 
enable a rigorous and systematic assessment of the applicability domain of the zebrafish 
from both a mechanistic and phenotypic standpoint. This will increase the confidence in 
its application for the early detection of adverse drug reactions in any major organ system.
Keywords: drug safety, cardiovascular effects, zebrafish, preclinical species, meta-analysis, comparative 
pharmacology, beta-adrenergic receptor, renin–angiotensin system
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INTRODUCTION
A considerable number of drug candidates have the potential 
to alter cardiovascular functions at therapeutically relevant 
concentrations. Predicting those effects as early as possible 
during drug development is critically important to ensure the 
progression of safer compounds through the pipeline and to 
minimize the risk of cardiovascular safety liabilities emerging 
at later stages of development (Laverty et al., 2011; Cook et al., 
2014; Lester and Olbertz, 2016). The fast-paced advancements 
ongoing in the development of human-based in silico and in 
vitro predictive approaches hold great promise for improving 
the early detection of drug-induced cardiovascular alterations, 
including cardiotoxicity (Clements et al., 2015; Colatsky et al., 
2016; Gintant et al., 2016; Land et al., 2017; Passini et al., 2017). 
However, to date, the use of in vivo preclinical models is still a key 
aspect of cardiovascular efficacy and safety assessment (Fliegner 
et al., 2015; Vargas et al., 2015; Berridge et al., 2016), mainly 
because of the ability of in vivo testing to capture integrated 
multiscale processes that cannot be observed outside an intact 
organism. These processes include pharmacokinetic-dependent 
and metabolism-mediated effects, chronic or delayed toxicity, 
vascular and hemodynamic alterations, as well as interaction 
between cardiovascular, nervous, and renal systems (Holzgrefe 
et al., 2014).
In this context, the identification of the most suitable 
preclinical animal model represents a central challenge for 
the design of a successful testing strategy, as this choice can 
profoundly affect the translational value of each experiment 
and, in turn, data interpretation and subsequent decision-
making (Denayer et al., 2014; Holzgrefe et al., 2014). From a 
cardiovascular perspective, dog and nonhuman primates (e.g., 
cynomolgus monkey) are the most commonly used nonrodent 
models, as their physiology is considered the most relevant to 
humans (Leishman et al., 2012; Holzgrefe et al., 2014). Other 
test species include minipig (Bode et al., 2010), marmoset (Tabo 
et al., 2008), and guinea pigs (Marks et al., 2012). Beside these 
models, small rodent species (i.e., rat and mouse) remain the 
most popular choice to investigate cardiovascular physiology and 
disease, genetics, and pharmacology (Camacho et al., 2016). As 
with any animal model, each species mentioned above has both 
advantages and limitations (e.g., see Holzgrefe et al. (2014) and 
Milani-Nejad and Janssen (2014) for extensive reviews of these 
aspects); however, common limitations include high ethical and 
financial costs, and low throughput potential.
In recent years, extensive research efforts have been allocated 
worldwide to identify potential alternative testing approaches 
that may lead to the reduction, replacement, or refinement (3Rs) 
of the model species mentioned above. Within this research 
theme, the zebrafish has emerged as a new, potentially valuable, 
model for the in vivo assessment of a variety of human-relevant 
drug-induced effects, including cardiovascular alterations 
(Parker et al., 2014; MacRae and Peterson, 2015). Zebrafish 
are characterized by a number of valuable features, including 
relatively inexpensive maintenance costs, amenability to genetic 
manipulation, high conservation of human drug targets (i.e., 
>82%; Howe et al., 2013; Verbruggen et al., 2017), and of a broad 
range of human-relevant phenotypes that can be modified by 
pharmacological treatment (MacRae and Peterson, 2015).
Considering the high impact of unpredicted cardiotoxicity 
on drug development (Laverty et al., 2011), the availability 
of a simpler vertebrate model, such as zebrafish, may enable 
cardiovascular profiling of new drugs before commencing 
mammalian toxicity tests, thus serving as a bridge between 
early in vitro safety predictions and later in vivo preclinical 
testing. Several studies have started to explore this potential 
from a translational perspective, such as Parker et al. (2014) 
and Cornet et al. (2017). Despite encouraging results, to date, 
the implementation of zebrafish in existing testing strategies 
faces resistance not least because of uncertainty around the 
quantitative aspects of zebrafish cardiovascular responses 
compared with both mammalian preclinical species and humans. 
We propose that coordinated efforts to perform quantitative 
comparative assessment of those responses may help to clarify 
the translational value of zebrafish and help define its domain of 
applicability from both mechanistic and phenotypic standpoints.
The aim of the present study was to quantify the degree of 
similarity in the in vivo cardiovascular responses of zebrafish, 
rat, dog, and human to three model compounds (propranolol, 
losartan, and captopril), which act as modulators of two key 
systems (beta-adrenergic and renin–angiotensin systems) 
involved in the regulation of cardiovascular functions. To do so, 
we used in vivo imaging techniques to generate novel zebrafish 
experimental data. The latter were successively combined with a 
database of interspecies responses extracted from the literature 




Adult WIK-strain (wild-type India Kolkata) zebrafish were 
maintained in flow through aquaria under optimal spawning 
conditions. Embryos were collected from individual male–female 
pairs and cultured in Petri dishes to 7 days postfertilization 
(dpf), as described in Winter et al. (2008). A complete water 
change was carried out every 24 h ensuring that water quality 
was maintained until day 7, when the fish were used in the 
experiments. All experiments were conducted in temperature-
controlled laboratories held at 28 ± 1°C. Animals were treated 
in full accordance with the United Kingdom Animals (Scientific 
Procedures) Act regarding the use of animals in scientific 
procedures. All sections of this report adhere to the ARRIVE 
Guidelines for reporting animal research (Kilkenny et al., 2010). 
A completed ARRIVE guidelines checklist is included in the 
Supplementary Material Data Sheet 2.
Test Compounds and Reagents
All test compounds and reagents used were purchased from 
Sigma-Aldrich UK Ltd. Propranolol (CAS no. 318-98-9), losartan 
(CAS no. 124750-99-8), and captopril (CAS number 62571-86-2) 
were selected as model compounds because of their known 
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pharmacological activity (respectively, beta-adrenergic receptor 
antagonist, angiotensin 2 receptor antagonist, and angiotensin-
converting enzyme inhibitor) and for the public availability 
of preclinical data specifically relating to their effects on the 
cardiovascular system.
Determination of Maximum Tolerated 
Concentration (MTC)
Individual larvae were loaded into each well of 24-well 
microplates in a total volume of 500 μl of dechlorinated tap 
water (culture water). To determine the maximum tolerated 
concentration (MTC), each test compound was tested at 
seven different concentrations using eight zebrafish larvae per 
treatment group, in parallel with a solvent control group [0.5–1% 
(v/v) DMSO]. Test compounds were freshly prepared in 2% (v/v) 
DMSO in culture water, and the pH of stock test compound and 
controls was checked and adjusted to 7.4 using 1 M NaOH/1 M 
HCl, before subsequent dilution. The allocation of each exposure 
concentration to specific columns of the multiwell plate was 
randomized, as well as the allocation of individual zebrafish to 
individual wells. After 1 h, the MTC was defined using a series 
of qualitative indicators of animal health as previously outlined 
in Winter et al. (2008). Briefly, these were loss of dorso-ventral 
balance, abnormal morphology, larval touch responsiveness 
using a seeker, and mortality indicated by the absence of 
heartbeat.
Drug Administration for CV Assessment
The assessment of cardiovascular function was performed as 
previously described by Parker et al. (2014). Individual larvae 
FIGURE 1 | Summary of the methodological approach employed in the study. The experimental quantification of zebrafish (7 dpf) cardiovascular responses to 
propranolol, losartan, and captopril (left) was combined with the subsequent meta-analysis of mammalian preclinical and human data extracted from the literature 
(right) to generate quantitative understanding of interspecies similarities in effect size and direction.
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were loaded into each well of 24-well microplates in a total 
volume of 500 μl of culture water. Each compound was tested 
at four different concentrations using six larvae per treatment. 
Each experiment also included a solvent control group (0.5–
1% DMSO) with the same number of larvae. The selection of 
the concentration range used to assess dose responsiveness 
was driven by the MTC data so that the highest nonlethal 
concentration was used as the apical concentration in the final 
concentration-response experiments. The allocation of each 
exposure concentration to specific columns of the multiwell plate 
was randomized, as well as the allocation of individual zebrafish 
to individual wells. Two sets of independent experiments 
were performed to quantify drug-induced effects after 1 and 
48 h exposure. In the 1-h exposure experiments, propranolol 
was tested at 16, 32, 64, and 125 µM; losartan was tested at 
1.25, 2.5. 5, and 10 mM; captopril was tested at 6.25, 12.5, 25, 
and 50 mM. In the 48-h exposure experiment, propranolol 
was tested at 2, 4, 8, and 16 µM; losartan was tested at 0.625, 
1.25, 2.5, and 5 mM; captopril was tested at 6.25, 12.5, 25, and 
50  mM. Larvae were dosed by immersion at 30-min intervals 
so that they could be mounted individually, and cardiovascular 
function was assessed for 20 min. Each compound was tested 
over 2  days; on each day, three fish were assessed for each 
treatment group (n = 6). This design required the use of two 
different clutches of fish to minimize the risk of bias associated 
with clutch-specific sensitivity.
Preparation of Animals and Video Capture
As previously stated, the detailed methodology used for the in 
vivo quantification of cardiovascular function is identical to 
that described by Parker et al. (2014). Briefly, following drug 
exposure, each larva was anesthetized with 0.1  mg/ml MS222 
(pH 7.5) until dorso-ventral balance was lost, rapidly transferred 
into low melting point agarose (10 mg/ml, held as a liquid at 
35°C), and then deposited in a total volume of 80 μl into a single 
well created by a press-to-seal silicon isolator (Sigma-Aldrich, 
Poole, UK) on a clear microscope slide. The orientation of the 
larva was gently adjusted to offer a lateral view with its head to the 
left. To maintain the position, the agarose was rapidly solidified 
by a brief exposure to a cooling plate set at 5°C. Two drops of 
MS222 were placed on top, followed by a coverslip to minimize 
evaporation and gel contraction. The slide was then transferred to 
an inverted light microscope (Leica DM IRB, Leica Microsystems 
UK Ltd., 5X objective) fitted with two high-speed video cameras. 
One camera was positioned to capture the whole heart at 30 
frames per second (fps) (Grasshopper® GRAS-50S5C-C) and the 
second to capture the dorsal aorta, caudal to the swim bladder, 
at 120 fps (Grasshopper® GRAS-03K2M-C). Both cameras were 
independently focused on their respective regions of interest to 
ensure optimal image quality and set to record simultaneously 
for 20 min.
Analysis of Cardiac and Vascular 
Parameters
Heart videos were analyzed using MicroZebraLab™ (v3.5, 
ViewPoint, Lyon, France). The software provides beat 
frequencies for each chamber, allowing the determination 
of the global heart rate (atrial and ventricular beat rates per 
minute or ABR and VBR, respectively), as well as the detection 
of potential arrhythmias (e.g., A–V decoupling) via the 
quantification of atrium–ventriculum beat ratio (A–V beat 
ratio). Blood flow videos were analyzed using ZebraBlood™ 
(v1.3.2, ViewPoint, Lyon, France), which enabled quantification 
of changes in blood vessel diameter (i.e., dorsal aorta diameter, 
DA diameter) and dorsal aorta blood flowrate (DA flow), 
as described by Parker et al. (2014). A surrogate measure of 
cardiac stroke volume (surrogate stroke volume, SSV) was 
calculated by dividing the dorsal aorta flow rate (in nl/s) by 
the VBR per second (bpm/60), as also previously described in 
Parker et al. (2014).
Analysis of Zebrafish Cardiovascular Data
Statistical analyses were conducted using GraphPad Prism 7 
software. Data were analyzed for normality (Kolmogorov–
Smirnov test) and homogeneity of variance (Levene’s test). 
Where the assumptions for parametric testing were met, one-
way analysis of variance (ANOVA) was undertaken, followed 
by the Dunnett’s test to compare the treatment means with 
respective controls. Where the assumptions were not met, 
data were analyzed using a Kruskal–Wallis ANOVA on Ranks, 
followed by Dunn’s post hoc test. Power analysis was performed 
using the Experimental Design Assistant (EDA) online tool 
operated by the UK National Centre for the Replacement, 
Refinement and Reduction of Animals in Research (NC3Rs) 
(https://eda.nc3rs.org.uk) (Sert et al., 2017) to estimate the 
endpoint-specific minimum effect size likely to be detected with 
n = 6. The latter was calculated using endpoint-specific mean 
and standard deviation observed in the control populations, 
with power set at 0.80 and significance level (alpha) set at 0.05 
(two-sided test).
Meta-Analysis
The objective of the meta-analysis was to estimate drug-induced 
effect size and effect direction (increase or decrease) across four 
different species (zebrafish, rat, dog, and human) using data 
collected from publicly available literature.
Data Sources and Literature Search
A literature search via PubMed and Google Scholar was 
performed between January 2017 and January 2018 to identify 
experimental studies that quantified the effects of propranolol, 
losartan, and captopril on four cardiovascular parameters (heart 
rate, blood flow, stroke volume, and blood vessel diameter) in 
four species (zebrafish, dog, rat, and human). The search was 
performed using a combination of keywords (drug name + 
endpoint name + species) and was restricted to English language 
publications only. Studies were included if they reported 
quantification of one or more of the target endpoints in both 
control and drug-treated subjects. Specifically, the minimum 
amount of information necessary for inclusion consisted of 
number of experimental subjects, mean value, and standard 
deviation, in both control and treated groups.
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Data Extraction and Database Quality Assessment
The data and information extracted from each relevant 
publication included species, study design, sample size of control 
group, sample size of treatment group, mean value and standard 
deviation of control group, mean value and standard deviation 
of treatment group, dose, administration route, treatment 
duration, and pathological status of the experimental subjects 
(e.g., healthy vs. disease models). For the studies that reported 
dose and/or time responses, each dose and/or time point was 
considered an independent data point in the subsequent meta-
analysis. A quality assessment of all extracted data and relative 
database was performed to evaluate the consistency between 
extracted data and original values. All identified inconsistencies 
were resolved before the final analysis. The zebrafish data 
generated here, in our zebrafish experiments, were also included 
in the database.
Data Synthesis and Statistical Analysis
Extracted data were combined for meta-analysis using Open 
Meta-Analyst software (by Center of Evidence Based Medicine 
http://www.cebm.brown.edu/openmeta/). For each endpoint, 
subgroup meta-analyses were conducted using a random 
effect model according to the DerSimonian–Laird method 
(DerSimonian and Laird, 1986). Each species represented a 
subgroup. Forest plots were generated to summarize the effect 
size estimates (expressed as standardized mean differences, 
SMD) and their 95% confidence intervals for each of the four 
species. These figures include measures of heterogeneity across 
studies (I2 statistic) and a test for overall effect.
RESULTS
Drug-Induced Cardiovascular Effects in 
Zebrafish
To test the effects of the three model drugs on zebrafish 
cardiovascular functions, we used in vivo imaging to quantify 
the response of six cardiovascular parameters after 1 and 48  h 
of exposure. A visualization of the six endpoints as integrated 
cardiovascular functional outputs is displayed in Figure 2, whereas 
Figure 3 shows the entire set of in vivo data generated during the 
study. Considering the interdependence of the cardiovascular 
parameters considered in this study, the double visualization 
strategy of the same data allowed us to evaluate both individual 
endpoints and the integrated cardiovascular responses to the drug, 
facilitating the interpretation of the data and the detection of shifts 
from average control physiology. This profiling approach also 
enabled a more effective interdrug comparison. Mean, minimum, 
and maximum values quantified in each experimental group are 
summarized in the Supplementary Tables 1-6 (Supplementary 
Material Data Sheet 1). The estimated endpoint-specific 
minimum effect size values (%) likely to be detected with n = 6, 
FIGURE 2 | Integrated representation of the effects induced by propranolol (125 µM), losartan (5 mM), and captopril (50 mM) on six cardiovascular endpoints 
measured in zebrafish larvae (7 dpf), after 1 and 48 h exposure. Each graph represents the effect size observed for each endpoint in treated fish (red) versus 
control fish (blue), expressed as ratio between mean treated value and mean control value. For example, a treated value of 1.1 indicates a 10% increase versus the 
control value.
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FIGURE 3 | Dose–response of five cardiovascular parameters measured in zebrafish larvae (7 dpf) following exposure to propranolol, losartan, and captopril after 
two different exposure times (1 and 48 h). Data are presented as mean ± SEM (n = 4–6). Statistically significant differences from the control group are displayed as 
*(p < 0.05).
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for each endpoint/drug/time combination, are provided in 
Supplementary Table 7 (Supplementary Material Data 
Sheet  1). In the following sections, we describe, in detail, the 
effects of each compound on the cardiovascular system of each of 
the model species evaluated. It is worth noting that, in addition 
to effects showing statistical significance, we have also included 
some discussion of nonstatistically significant effects that, in the 
context of our meta-analysis, were considered to be of biological 
importance. Our justification for this approach is that we 
hypothesized that even small (for example, 10–20%) changes in 
the cardiovascular parameters considered here are likely to have 
high biological impact, for example a positive therapeutic effect 
for the patient (Cucherat, 2007; Leucht et al., 2015). This is an 
ongoing issue with the interpretation of data from animal studies 
in which relatively small numbers of test subjects are typically 
employed, in contrast to the need for large-scale clinical trials to 
demonstrate, in many cases, what are relatively small therapeutic 
advantages.
Propranolol
Fish exposed to propranolol for 1 h (Figure 2, Figure 3) 
displayed a clear dose-dependent decrease in both ABR and 
VBR, and the effect was statistically significant at the two highest 
drug concentrations (64 and 125 µM: at 64 µM, ABR: −17 ± 7%, 
p = 0.014; VBR: −17 ± 7%, p = 0.047; at 125 µM, ABR: −33 ± 
13%, p < 0.0001; VBR: −33 ± 12%, p < 0.0001). Exposure to 
the highest drug concentration (125 µM) also resulted in a 
significant increase in surrogate stroke volume (SSV: +75 ± 48%, 
p = 0.003), whereas nonsignificant increases were observed for 
dorsal aorta diameter (+11 ± 9%) and flow (+26 ± 28%). The 
atrium–ventriculum (A–V) beat ratio was not affected at any 
concentration. In contrast to the 1-h exposure, exposure for 
48 h reversed the direction of the effect on dorsal aorta diameter 
and flow, resulting in a dose-dependent decrease in dorsal aorta 
flow, which reached −44 ± 20% of control values (p = 0.023) at 
the highest concentration (16 µM) (Figure 2). Exposure to the 
same concentration resulted in a nonsignificant reduction in 
dorsal aorta diameter (−9 ± 7%). Significant reductions of both 
atrial and ventricular beat rate (p < 0.001) were observed at all 
exposure concentrations (2, 4, 8, and 16 µM). The magnitude of 
the decrease was approximately −40 ± 13% of control values at 
the highest exposure concentration.
Losartan
Exposure to losartan for 1  h did not result in any statistically 
significant effects on any of the measured endpoints (Figures 2 
and 3). The highest effect size was observed for dorsal aorta 
flow (+32% ± 34%) and surrogate stroke volume (+30% ± 36%) 
after exposure to 5 mM, but within-group variability meant that 
these effects did not achieve statistical significance. Conversely, 
exposure to losartan for 48 h resulted in the significant reduction 
of both atrial and ventricular beat rate in zebrafish exposed to 
the highest concentration (5 mM) (ABR: −17 ± 5%, p = 0.0006; 
AVR: −17 ± 5%, p = 0.0012). Surrogate stroke volume was also 
increased at the lowest and highest concentration only by 34 ± 
21% and 30 ± 33%, respectively, although this effect was not 
statistically significant.
Captopril
Exposure to captopril for 1 h (Figures 2 and 3) resulted in a 
significant decrease in dorsal aorta blood flow and surrogate 
stroke volume at 6.25 mM (DA blood flow: −43 ± 13%; p = 
0.0350; SSV: −39 ± 15%, p = 0.0213). The decrease in both 
parameters was also observed at higher exposure concentrations, 
although in this case, the effect was not statistically significant. A 
nonsignificant increase in dorsal aorta diameter (+10 ± 9%) was 
also observed in fish exposed to the highest drug concentration 
(50 mM). No effects were observed, however, for atrial and 
ventricular beat rate or A–V beat ratio. Exposure to captopril for 
48 h only resulted in nonsignificant dose-dependent trends: an 
increase in DA diameter, which reached an effect size of +13 ± 
18% after exposure to 50 mM and a decrease in DA flow, which 
reached an effect size of −31 ± 29% after exposure to 25 mM.
Time-Dependent Changes of Zebrafish 
Cardiovascular Parameters in the Control Group
In 3 out of 15 cases, the values of cardiovascular parameters in 
control zebrafish were significantly different in the 1- and 48-h 
exposure experiments. Specifically, DA blood flow and SSV in the 
losartan-treated group (i.e., higher values observed at 48 h; p < 
0.05) and DA diameter in the captopril-treated group (i.e., lower 
values observed at 48 h; p < 0.05). It is important to note that the 
1- and 48-h exposures to the test compounds were carried out 
as independent experiments. These statistical differences are lost 
once the experiment-specific control values are compared to the 
historical control data pooled from the six different experiments 
described here. This suggests that the observed differences fall 
within the normal interexperiment variability observed in 
zebrafish laboratories and, in this case, is unlikely to affect the 
interpretation of drug-mediated effects.
Meta-Analysis of Effect Size and Direction 
in Zebrafish, Rat, Dog, and Human
To investigate the relevance of zebrafish cardiovascular responses 
to those observed in two preclinical mammalian species (rat, 
dog), as well as in humans, we performed a quantitative meta-
analysis across four endpoints: heart rate, blood flow, surrogate 
stroke volume/stroke volume, and blood vessel diameter. We 
identified a total of 23 suitable studies for propranolol (Table 1), 
18 for losartan (Table 2), and 31 for captopril (Table 3). 
Beyond the data generated here, the only relevant zebrafish data 
identified in the literature referred to the effects of propranolol 
on zebrafish heart rate (i.e., three studies). The database of 
the extracted data and the characteristics of each study are 
provided in the Supplementary Material Table 1. As expected, 
during data extraction, we observed a wide diversity of 
experimental conditions used across studies including different 
doses, administration routes (intravenous, oral), underlying 
health status of the experimental subjects (e.g., healthy vs. 
disease models), data collection procedures (e.g., invasive vs. 
noninvasive), and duration of the treatment (e.g., from bolus 
dosage to sustained administration over several months). This 
diversity resulted in a significant heterogeneity of the dataset; 
nonetheless, our objective was specifically to establish whether 
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drug-induced effects in zebrafish were comparable in terms of 
effect size and direction to the ones observed in other species, 
rather than performing an accurate analysis of the efficacy of the 
drug. For this reason, to minimize potential artifacts deriving 
from subselection of specific conditions, we included all available 
data in the analysis. Figures 4, 5, 9, and 10 display a simplified 
standardized mean difference for each drug and for each 
species. Figures 6, 7, and 8 display the detailed meta-analysis of 
drug effects on blood flow, one of the two endpoints (together 
with stroke volume) for which we observed a divergence of 
zebrafish response to captopril from that observed in mammals. 
The detailed meta-analysis of all the other drug-endpoint 
combinations is provided in the Supplementary Material Data 
Sheet 1 (Supplementary Figures 1–9).
TABLE 1 | List of studies involving the treatment of different species with propranolol.
Species Study Endpoint* Control sample size Treatment sample size Health status of the 
experimental subjects
Human Bellissant et al., 1994 HR, BF, VD, SV 6–7 6–7 Healthy
Human Crawford et al., 1980 HR 10–19 10–19 Healthy
Human Danesh et al., 1984 BF 7 7 Disease
Human Le Winter et al., 1975 HR 10 10 Healthy
Human Marshall et al., 1981 HR 7 18 Healthy/disease
Human Mo et al., 2011 HR 126 126 Healthy/disease
Human Morris et al., 1983 HR 22 22 Disease
Human Port et al., 1980 HR, SV 12 12 Healthy
Human Saigal et al., 1998 HR, BF, VD 10 10 Disease
Human Zain-Hamid et al., 2003 HR, BF, VD 12 4 Disease
Dog Berdeaux et al., 1991 HR, BF, VD 7 7 Healthy
Dog Driscoll et al., 1982 HR, BF, SV 9–10 9–10 Healthy
Dog Kuhn et al., 1990 BF, VD, SV 6 6 Healthy
Dog Vigue et al., 1993 HR, BF, VD 6 6 Healthy
Dog Willems et al., 1986 HR, BF 8 8 Disease
Rat Chillon and Baumbach, 1999 VD 16 13 Disease
Rat Gay et al., 1990 HR, SV 12 10 Healthy/Disease
Rat Hatzinikolaou et al., 1983 HR, SV 7 7 Healthy
Rat Rochette et al., 1987 HR, BF, SV 6 6 Healthy
Rat Skinner et al., 1996 HR, BF 5–9 7–9 Healthy/disease
Zebrafish Finn et al., 2012 HR 20 20 Healthy
Zebrafish Fraysse et al., 2006 HR 48 48 Healthy
Zebrafish Schwerte et al., 2006 HR 7 7 Healthy
Zebrafish Present study HR, BF, VD, SV 4–6 4–6 Healthy
*HR, #Heart rate; BF, Blood flow; VD, Vessel diameter; SV, Stroke volume.
TABLE 2 | List of studies involving the treatment of different species with losartan.
Species Study Endpoint* Control sample size Treatment sample size Health status of the 
experimental subjects
Human Craft, 1997 HR, SV 6 6 Disease
Human Crozier et al., 1995 HR 26 22–29 Disease
Human Hartog et al., 2016 HR, SV 19–42 19–42 Disease
Human Gismondi et al., 2015 VD 16 16 Disease
Human Keković et al., 2012 HR 30 30 Disease
Human Konstam et al., 2000 HR 13 13 Disease
Human Schiffrin et al., 2000 VD 9 9 Disease
Human Paterna et al., 2000 BF 18 18 Disease
Dog Lambert, 1995 HR 6 6 Healthy
Dog Lynch et al., 1999 HR 8 8 Disease
Dog MacFadyen et al., 1992 HR 16 16 Disease
Dog Sudhir et al., 1993 HR, BF, VD 6 6 Healthy
Dog Suzuki et al., 2001 HR, SV 5 5 Disease
Rat Azevedo et al., 2003 HR, SV 16 11 Disease
Rat De Angelis et al., 2005 HR, BF, SV 6 6 Healthy
Rat Koprdova et al., 2009 VD 6 6 Healthy/disease
Rat Matrougui et al., 2000 VD 7 7 Healthy/disease
Rat Song et al., 2015 HR 6 6 Healthy
Zebrafish Present study HR, BF, VD, SV 4–6 4–6 Healthy
*HR, Heart rate; BF, Blood flow; VD, Vessel diameter; SV, Stroke volume.
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Interspecies Drug-Induced Effects on Heart Rate
Treatment with the beta-adrenergic receptor antagonist propranolol 
was associated with a significant decrease of heart rate in all species 
(Figure 4). The effects observed in zebrafish were comparable with 
those in other species, both in terms of effect direction (dose–
response decrease) and effect size (standardized mean difference 
(SMD): zebrafish-1h = −1.84; zebrafish-48h = −3.46; zebrafish-
other studies = −1.79; rat = −4.31; dog = −2.92; human = −1.71). 
Conversely, the effects of the angiotensin II receptor antagonist 
losartan were less clear (Figure 4), with observed SMDs oscillating 
between negative and positive values in all species, except for 
zebrafish treated for 48 h (SMD: zebrafish-1h = +0.45; zebrafish-
48h = −1.14; rat = −0.07; dog = +0.36; human = −0.30). For all 
species, whereas some studies reported a decrease in heart rate, 
others reported an increase. Despite these discrepancies, overall 
zebrafish responses after 1 h of exposure were broadly comparable 
with the effect range observed in mammals. The effects on heart 
rate were more consistent when the renin−angiotensin system 
was modulated at the level of the angiotensin-converting enzyme 
by the ACE inhibitor captopril (Figure 4). Treatment with this 
compound was associated with an overall decrease in heart rate 
in all species, with only two exceptions, represented by one study 
in humans (Burgraaff et al., 1998) and one in dogs (Lynch et al., 
1999) (SMD: zebrafish-1h = −0.64; zebrafish-48h = −1.21; rat = 
−1.29; dog = −0.65; human = −0.39). Furthermore, in this case, 
zebrafish responses were directly comparable with those observed 
in mammals.
Interspecies Drug-Induced Effects on Blood Flow
Treatment with propranolol, in the vast majority of cases, was 
associated with a significant decrease in blood flow in all species 
(Figure 5; Figure 6; SMD: zebrafish-1h = +0.32; zebrafish-48h = 
−1.21; rat = −1.66; dog = −1.02; human = −0.70), although a small 
number of studies across all species reported an increase in blood 
flow in some of the experimental groups (human: Bellissant et al., 
1994; dog: Driscoll et al., 1982; rat: Rochette et al., 1987; Skinner 
et al., 1996; zebrafish: present study—zebrafish-1h). In those 
cases, the highest SMD was +0.98 for zebrafish-1h, +2.48 for rat, 
+0.36 for dog, and +0.70 for human.
Conversely, the meta-analysis revealed that pharmacological 
modulation of the renin–angiotensin system by losartan was 
associated with an overall positive effect on blood flow in all 
species (Figures 5 and 7). SMD values for losartan were as follows: 
zebrafish-1h = +0.66; zebrafish-48h = +0.11; rat = +2.52; dog = 
+1.81; human = +0.32. However, only one study, including multiple 
data points, was identified for each species for this specific endpoint; 
thus, these findings should be treated with caution (human: Paterna 
et al., 2000; dog: Sudhir et al. 1993; rat: De Angelis et al., 2005).
TABLE 3 | List of studies involving the treatment of different species with captopril.
Species Study Endpoint* Control sample size Treatment sample size Health status of the 
experimental subjects
Human Aznaouridis et al., 2007 VD 25 25 Disease
Human Burggraaf et al., 1998 HR, BF 9 9 Healthy
Human Chau et al., 1992 VD 8 8 Disease
Human Cleland et al., 1991 HR 16 16 Disease
Human Leier et al., 1983 SV 7 7 Disease
Human Massie et al., 1982 HR, SV 14 14 Disease
Human Sturani et al., 1982 HR 15 15 Disease
Human Vandenburg et al., 1983 HR 9 9 Disease
Human Konstam et al., 2000 HR 16 16 Disease
Human Schreij et al., 1996 BF 8–50 8–50 Disease
Human Van den Broek et al., 1995 BF 9 9 Disease
Human Schanzenbacher and Liebau, 1983 SV 9 9 Disease
Dog Blackford et al., 1990 SV 10 5 Disease
Dog Jugdutt, 1995 HR 12 12 Disease
Dog Lynch et al., 1999 HR 9 10 Disease
Dog Satoh et al., 1980 BF 8 8 Healthy
Dog Shannon et al., 1997 HR, BF 5–9 5–9 Disease
Dog Wong et al., 1981 BF 9 9 Disease
Dog Zimmerman et al., 1982 BF 6 6 Disease
Rat Silva et al., 2002 HR 10 7–10 Healthy
Rat Freslon and Giudicelli, 1983 VD 10 10 Disease
Rat Jin et al., 2001 HR 6 6 Disease
Rat Kimura et al., 1991 VD 5–6 5 Disease
Rat Koike et al., 1980 BF 7 6–7 Disease
Rat Miguel-Carrasco et al., 2010 HR 6 6 Healthy
Rat Pfeffer et al., 1982 SV 11–13 9 Healthy/disease
Rat Pfeffer et al., 1985 SV 8–36 8–23 Healthy/disease
Rat Raya et al., 1989 HR 9 7 Disease
Rat Rozsa and Sonkodi, 1995 BF 10 10 Healthy/disease
Rat Skinner et al., 1996 HR, BF 6–14 6 Healthy/disease
Rat Wang and Prewitt, 1991 VD 9–11 9–11 Healthy
Zebrafish Present study HR, BF, VD, SV 4–6 4–6 Healthy
*HR, Heart rate; BF, Blood flow; VD, Vessel diameter; SV, Stroke volume.
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Differently from the responses to propranolol and losartan, 
zebrafish responses to the ACE inhibitor captopril revealed an 
overall inconsistency between zebrafish and mammalian changes 
in blood flow. In fact, captopril induced a consistent decrease in 
blood flow in zebrafish after both 1- and 48-h exposure, whereas 
the overall effect was positive in rat and dog and close to zero 
in humans (Figure 5, Figure 8; SMD: zebrafish-1h = −1.22; 
zebrafish-48h = −0.87; rat = +0.50; dog = +0.86; human = +0.05). 
Interestingly, one study using rat (Skinner et al., 1996) and one 
in dog (Shannon et al. 1997) also reported a significant decrease 
in blood flow after treatment with captopril (lowest SMD, −3.40 
and −1.09, respectively).
Interspecies Drug-Induced Effects on Blood Vessel 
Diameter
Both adrenergic- and angiotensin-mediated mechanisms are 
known to be involved in the regulation of vasocontraction and 
vasodilation. Although the pharmacological modulation of 
the renin–angiotensin system via losartan and captopril was 
associated with the predicted effect (i.e., vasodilation), beta-
adrenergic modulation via propranolol treatment produced 
conflicting results both within, and between species (Figure  9). 
The vasodilation induced by losartan was observed in all species, 
with striking similarities between zebrafish, dog, and humans, both 
in terms of effect direction, and magnitude (SMD: zebrafish-1h = 
+0.58; zebrafish-48h = +0.54; rat = +0.22; dog = +1.41; human = 
+0.61). The vasodilation induced by captopril was more obvious 
in rat than in other species, although no data were available from 
dog studies (SMD: zebrafish-1h  =  +0.31; zebrafish-48h = +0.87; 
rat = +2.03; human = +1.36). Only two human studies were 
identified, of which one showed no effects (SMD = +0.007) and 
one significant vasodilation (SMD = +2.86). The effect induced by 
propranolol on blood vessel diameter regulation was not as clear as 
that observed for both losartan and captopril. The observed SMDs 
for propranolol were as follows: zebrafish-1h = +0.166; zebrafish-
48h = −0.37; rat = +4.30; dog = −1.16; human = +0.02. At an 
intraspecies level, both in zebrafish and human, some treatments 
induced vasodilation, whereas others resulted in vasoconstriction 
(min–max CI: zebrafish-1h = −0.33/+1.04; human: −1.17/+0.92). 
In the case of the zebrafish, vasoconstriction was observed at the 
lowest exposure concentration, whereas vasodilation occurred at 
the higher levels. At an interspecies level, studies performed in rat 
and dog showed diametrically opposite effects, with significant 
vasodilation in rat (SMD = +4.30) and consistent vasoconstriction 
in dog (SMD = −1.16).
Interspecies Drug-Induced Effects on (Surrogate) 
Stroke Volume
Treatment with propranolol induced contrasting intraspecies 
changes in stroke volume (in the case of zebrafish, measured 
FIGURE 4 | Overview of the effects of propranolol, losartan, and captopril on the heart rate of human, dog, rat, and zebrafish. Data are expressed as standardized 
mean difference (treated vs. control) ± 95% confidence interval. The data related to human, dog, and rat were retrieved from the literature, whereas the zebrafish 
data were generated in the present study. Each data point represents a different treatment group. The same dataset was used to perform a quantitative meta-
analysis. A detailed description of the results is provided in the Supplementary Material Data Sheet 1.
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as surrogate stroke volume) (Figure 10; SMD: zebrafish-1h = 
+0.89; zebrafish-48h = −0.04; rat = −0.23; dog = −0.14; human = 
−0.03). All species displayed both increased and decreased 
values for the same endpoint (min–max SMD: zebrafish-1h = 
−0.26/+2.88; zebrafish-48h = −0.50/+0.21; rat = −3.85/+2.40; 
dog = −0.87/+1.11; human = −2.21/+1.63). Losartan treatment 
was associated with an overall increase in stroke volume in all 
species (Figure 10; SMD: zebrafish-1h = +0.58; zebrafish-48h = 
+0.57; rat = +0.36; dog = +0.99; human = +0.084). A similarity 
was observed between zebrafish and mammalian responses, 
both in terms of effect direction and size. Conversely, the 
zebrafish response to captopril tended to be in contrast with the 
mammalian responses, particularly with those measured in rat 
and human (Figure 10; SMD: zebrafish-1h = −1.33; zebrafish-
48h = −0.52; rat = +2.03; dog = −0.08; human = +0.28).
DISCUSSION
Here, we provide evidence that zebrafish cardiovascular responses 
to propranolol, losartan, and captopril are largely in agreement 
with those observed in humans, both in terms of effect size and 
direction, revealing a striking similarity between the two species. 
Specifically, zebrafish responses recapitulated those observed in 
humans, in terms of both effect size and direction, in over 80% 
of the cases we assessed. However, in some of these cases, the 
evaluation of the similarity of the effect direction is not univocal, 
as the same drug caused contrasting effect directions within 
the same species. In those cases, our comparability assessment 
was based on the range of observed effects rather than on the 
standardized mean effect direction.
Beta-adrenergic receptors are key regulators of cardiovascular 
homeostasis. Beta-blockers, such as propranolol, cause a 
competitive inhibition of the beta-adrenergic receptors, 
countering the effects of catecholamines (Ladage et al., 2013). 
The clinically relevant outcomes of such inhibition include the 
reduction of heart rate and force of cardiac muscle contraction. In 
teleost fish, the beta-adrenergic system mediates a diverse range 
of functions as it does in humans, including the modulation of 
cardiac output (Altimiras et al., 1995), cardio-ventilatory responses 
(McKenzie et al., 1995), metabolic regulation (Van Heeswijk et al., 
2006), and skeletal muscle performance (McDonald et al., 1989). 
In 2007, Owen et al. reviewed the comparative pharmacology 
of beta-adrenergic receptor antagonists in fish and humans, 
highlighting not only the apparent high degree of functional 
and evolutionary conservation of the beta-adrenergic system but 
also the need to advance the understanding of beta-adrenergic-
mediated functions in fish species (Owen et al., 2007). Recorded 
observations of beta-blockers-induced cardiovascular effects 
in fish date back to the 1960s (Randall and Stevens, 1967). In 
FIGURE 5 | Overview of the effects of propranolol, losartan, and captopril on the blood flow of human, dog, rat, and zebrafish. Data are expressed as the 
standardized mean difference (treated vs. control) ± 95% confidence interval. The data from human, dog, and rat were retrieved from the literature, whereas the 
zebrafish data were generated in the present study. Each data point represents a different treatment group. The same dataset was used to perform a quantitative 
meta-analysis. A detailed description of the results is provided in the Supplementary Material Data Sheet 1.
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the 1970s, Payan and Girard (1977) used perfusion techniques 
and exposure to two adrenergic blockers (phentolamine and 
propranolol) to dissect the individual contribution of alpha and 
beta-adrenergic responses to the vasodilatory effects induced by 
epinephrine in the trout. Subsequent experiments with zebrafish 
larvae have mainly been focused on the heart, demonstrating that 
propranolol decreases heart rate (Fraysse et al., 2006; Schwerte 
et al., 2006; Finn et al., 2012) without alteration of QT interval 
(Milan et al., 2006). Our data not only confirmed previous 
observations but also shed new light on the time-dependent 
effects of the drug on an a set of other important cardiovascular 
parameters—such as blood flow, atrium–ventriculum beat ratio, 
aorta diameter, and stroke volume—providing an integrated 
profile of the drug-mediated cardiovascular effects that would be 
FIGURE 6 | Meta-analysis of the effects of propranolol on blood flow in zebrafish, rat, dog, and humans. Effect size reported as standardized mean difference ± 
95% confidence interval.
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difficult to obtain using mammalian preclinical species (Parker 
et al., 2014).
It is important to note that the effects observed in zebrafish 
after 1 h exposure to propranolol were sometimes different 
from those observed after 48 h exposure. For example, whereas 
the inhibitory effect of propranolol on heart rate was consistent 
at both time points, the effect on dorsal aorta blood flow shifted 
from positive to negative, and the increased surrogate stroke 
volume observed at 1 h returned to control values after 48 h of 
exposure. These differences are likely driven by a combination of 
pharmacokinetic (PK) and pharmacodynamic (PD) processes 
(Vauquelin and Charlton, 2010). Human and preclinical 
mammalian studies are generally performed by administering a 
single dose or repeated doses of drug at regular intervals orally 
or via injection. Conversely, zebrafish experiments are mainly 
carried out using immersion exposure in which the animals 
remain in contact with the drug continuously until the end of 
the experiment. The different administration strategies adopted 
in different experiments is likely to produce different PK/PD 
profiles both within one species and among different species, 
which may act as confounding factor and affect the translational 
value of the experiments. If the tested drug is chemically stable 
in water, waterborne exposure is likely to produce sustained 
(rather than oscillatory) internal drug concentrations in the 
zebrafish over time. In turn, this may generate exposure-specific 
drug/target interaction dynamics that can ultimately result 
in variable time-dependent phenotypic effects (Margiotta-
Casaluci et al. 2016). Beyond experiment-specific PK/PD 
considerations, it could be hypothesized that the propranolol-
mediated elevation of apical functional cardiovascular 
parameters (i.e., stroke volume and blood flow velocity) in 
healthy zebrafish may not be sustained for 48 h because of 
structural/energetic/compensatory limitations (Vatner et al., 
2000) despite the sustained blockade of the beta-adrenergic 
receptor. However, additional time-course experiments would 
be required to clarify this aspect. Considering the evidence 
discussed above, we propose that the potential confounding 
role of exposure dynamics should be explicitly considered as 
early as possible during the study design phase to maximize the 
translational value of future zebrafish experiments and avoid 
data misinterpretation.
Despite the potential differences between internal exposure 
dynamics in the different species considered in our analysis, 
the overlap between the range of zebrafish responses and those 
observed in humans appeared to be significant in terms of both 
effect size and direction, supporting previous suggestions of 
functional conservation of the beta-adrenergic receptor. These 
phenotypic observations are in line with the results obtained by 
Steele et al. (2011), who used gene knockdown experiments to 
characterize the role of the three different isoforms of zebrafish 
beta-adrenergic receptor (β1AR, β2aAR, and β2bAR) on larval 
cardiac function.
FIGURE 7 | Meta-analysis of the effects of losartan on blood flow in zebrafish, rat, dog, and humans. Effect size reported as standardized mean difference ± 95% 
confidence interval.
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FIGURE 8 | Meta-analysis of the effects of captopril on blood flow in zebrafish, rat, dog, and humans. Effect size reported as standardized mean difference ± 95% 
confidence interval.
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Considering the 10 clinical studies examined in our analysis, 
the administration frequency of propranolol to patients was as 
follows: four times per day/five studies; three times per day/one 
study; two times per day/one study; and single administration/
three studies. As drug administration frequency is only one of 
the many parameters that characterize the design of each study, 
this simple example serves to highlight the high heterogeneity in 
experimental conditions encountered during the data extraction 
phase. However, the meta-analysis of the effect size data and 
the related data visualization strategy employed in this study 
allowed us to identify and quantify emerging patterns for each 
specific cardiovascular response that could not be appreciated 
by considering only individual studies in isolation. A second 
advantage of the meta-analysis approach was the possibility 
to retrospectively identify and evaluate data points falling 
outside the predicted patterns of response. For example, the 
administration of propranolol appeared to produce contrasting 
effects on blood flow within the same species in humans, 
zebrafish, and rat. In the latter case, a closer evaluation of the 
data revealed that almost all data points indicating an increase of 
blood flow were generated by monitoring different areas of the 
brain of normotensive Wistar–Kyoto rats exposed to propranolol 
(Skinner et al., 1996). On the other hand, in the same study, all 
experiments carried out using spontaneously hypertensive rats 
caused a marked decrease in the same parameter. This example 
highlights the important role played by the health state of the 
animal model employed in the experiments and its potential to 
affect data interpretation and translational value. Considering the 
115 data points used in the cross-species analysis of propranolol-
induced effects in human, dog, and rat combined, 76 of those data 
points were generated using healthy subjects, whereas 39 were 
generated using subjects with altered cardiovascular physiology. 
The latter group included experiments carried out using patients 
with angina pectoris, myocardial ischemia, hypertension, and 
liver cirrhosis; rats displaying spontaneous hypertension or with 
induced myocardial infarction; and dogs with hypertension, 
hyperdynamic circulation, liver disease, or pretreated with 
isoproterenol (beta-adrenoreceptor agonist). It is important to 
consider that the zebrafish used in the present study were healthy 
animals tested under “normal” physiological conditions. It is 
plausible that the effect magnitude and sensitivity of some of the 
endpoints used in our analysis could have been augmented by 
introducing relevant alterations of the cardiovascular physiology 
(e.g., tachycardia, hypertension) or using relevant zebrafish 
cardiac disease models (Asnani and Peterson, 2014; Keßler et al., 
2015; Bournele and Beis, 2016).
The choice between healthy and disease models is generally 
driven by the aim of the specific study (e.g., safety vs. efficacy 
assessment); however, some target/phenotype associations 
may be more easily observable in a perturbed system rather 
FIGURE 9 | Overview of the effects of propranolol, losartan, and captopril on the blood vessel diameter of human, dog, rat, and zebrafish. Data are expressed 
as the standardized mean difference (treated vs. control) ± 95% confidence interval. The data related to human, dog, and rats were retrieved from the literature, 
whereas the zebrafish data were generated in the present study. Each data point represents a different treatment group. The same dataset was used to perform a 
quantitative meta-analysis. A detailed description of the results is provided in the Supplementary Material Data Sheet 1.
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than in healthy system. As discussed for the role of exposure 
dynamics, this factor should also be considered at the early stage 
of experimental design, as it may influence the statistical power 
of the experiment as well as the adopted testing strategy. The 
zebrafish cardiovascular profiling performed in the present study 
for the two renin–angiotensin system modulators, losartan and 
captopril, represents a good example of the challenge mentioned 
above. Losartan is an angiotensin II type 1 receptor antagonist 
(AT1 receptor) (Siegl et al., 1995), whereas captopril acts by 
inhibiting the angiotensin-converting enzyme (ACE) (Dzau, 
1990). Both AT1 receptor and ACE are two key components 
of the renin–angiotensin system (RAS), which regulates 
the homeostatic control of blood pressure, tissue perfusion, 
and extracellular volume (Atlas, 2007). Pathophysiological 
deregulation of the RAAS can lead to hypertension; thus, drugs 
such as losartan and captopril are used to pharmacologically 
modulate the RAS and, among the various effects, decrease blood 
pressure (Abraham et al., 2015). Pharmacodynamic responses 
common to both drugs include reduction of systemic vascular 
resistance via vasodilation, reduction in blood pressure, and 
increase in cardiac output (Israili, 2000; Abraham et al., 2015).
The statistical power of preclinical studies is a critically 
important factor driving costs and data interpretation. In the 
present study, carried out in zebrafish, both captopril and losartan 
appeared to cause vasodilation; however, none of the responses 
at any time point were statistically significant using six animals 
per treatment group. As a term of comparison, 35 and 89% of 
losartan data points for, respectively, rat and dog were generated 
using six or less animals. Conversely, these values are 45 and 68% 
for captopril, confirming the high heterogeneity of the dataset. 
Despite this uncertainty, when the effect size was compared 
across different species, we observed that both losartan and 
captopril induced effect magnitude ranges in zebrafish in line with 
those observed in rat, dog, and human studies. It is possible to 
hypothesize that a zebrafish model with induced vasoconstriction 
would likely facilitate the statistically significant detection of drug-
induced vasodilation using a similar, small number of animals.
At the same time, the overall observed pattern of response 
emerging from the meta-analysis may be partially explained by 
the structural boundaries that limit the maximum effect size of 
aorta diameter. For example, in humans, an aortic diameter 50% 
larger than baseline value is defined as ectasia, which results 
in aneurysm formation when the ectasia tolerance limits are 
exceeded (Hager et al., 2002; Erbel and Eggebrecth, 2006). If 
we also assume this definition is valid for zebrafish, it implies 
that a nonlethal drug-induced vasodilation is likely to be lower 
than 50% of control values. This hypothesis is in agreement with 
the average effect size observed in zebrafish exposed for 48 h to 
captopril (+16%) and losartan (+6%). As a term of comparison, 
the average vasodilation observed in mammalian species exposed 
FIGURE 10 | Overview of the effects of propranolol, losartan, and captopril on the stroke volume of human, dog, rat, and zebrafish. Data are expressed as the 
standardized mean difference (treated vs. control) ± 95% confidence interval. The data related to human, dog, and rat were retrieved from the literature, whereas the 
zebrafish data were generated in the present study. Each data point represents a different treatment group. The same dataset was used to perform a quantitative 
meta-analysis. A detailed description of the results is provided in the Supplementary Material Data Sheet 1.
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to losartan was +18% in rat studies, +20% in dog studies, and 
+10% in human studies. The detection of this type of effect size 
using standard statistics would require a higher statistical power 
than the one used in our experiment or alternatively the use of a 
model with proven extremely low interindividual variability with 
respect to the endpoint under investigation.
Beyond vessel diameter, the modulation of the RAS system 
by losartan and captopril exposure also produced consistent 
interspecies responses for heart rate, blood flow, and stroke volume. 
The only two cases where the zebrafish data and that from other 
models differed stemmed from the effect of captopril on blood flow 
and stroke volume, which displayed a moderate decrease instead of 
the neutral or positive effect observed in mammals. It is currently 
unclear whether these discrepancies are biologically meaningful, 
and additional studies should be carried out in the future to clarify 
this point. From an evolutionary standpoint, it is known that the 
RAS system is conserved in fish. Already in 1973, Nishimura and 
Ogawa, after reviewing the available evidence concerning the 
conservation of the RAS system in nonmammals, concluded that 
the components of the RAS system appeared to be evolutionary 
conserved in fish but raised doubts about the functional 
conservation of those components, such as their involvement in the 
sodium retaining processes observed in mammals (Nishimura and 
Ogawa, 1973). Subsequent studies have confirmed the evolutionary 
conservation of the RAS components in teleost fish (Fournier et al., 
2012), although the functional conservation of those components, 
to date, is still not fully understood. Several studies investigating 
the effects of RAS pharmacological modulation in fish models 
have generated conflicting results, which have led some authors to 
hypothesize a low conservation of the sartan binding site on the 
AT1 receptor (Fuentes and Eddy, 1996; Russell et al., 2001). Kitambi 
et al. (2009) focused on the vasculature of the eye and attempted 
a morpholino knockdown of the ACE gene in zebrafish; however, 
the experiment did not induce any obvious effect on eye blood 
vessel morphology, possibly due to an incomplete inhibition of 
ACE expression. In the same study, exposure of zebrafish larvae 
to the ACE inhibitor enalapril maleate induced vasodilation of 
intraocular blood vessels but not blood vessels in the trunk. On the 
other hand, many similarities between zebrafish and mammalian 
RAS-mediated functions also emerge from other studies. Rider et 
al. (2017) leveraged the advantages provided by transgenic zebrafish 
lines to demonstrate that mesonephric renin cells respond to RAS-
mediated challenges (including salinity challenge and captopril 
exposure) in a similar manner in both zebrafish and mammals. 
Kumai et al. (2014) demonstrated that the RAS is involved in Na+ 
homeostasis in zebrafish larvae. Our results were also generated 
using noninvasive in vivo imaging techniques measuring multiple 
endpoints simultaneously and suggest high similarity between 
zebrafish and mammalian cardiovascular responses mediated by 
AT1 receptor antagonism. ACE inhibition generated comparable 
responses only for the endpoint vasodilation and heart rate but not 
for stroke volume and blood flow, confirming, to some extent, the 
elusive nature of ACE functional conservation between teleost fish 
and mammals.
The comparison of the effect concentrations ranges of the 
different compounds tested in the present study brought to light an 
obvious difference between the three drugs. Whereas propranolol 
exerted cardiovascular effects in zebrafish in the micromolar 
range, losartan and captopril acted in the millimolar range. This 
gap is also observable in human Cmax values but to a much smaller 
extent (i.e., 2- to 10-fold difference) (Schulz et  al., 2012). This 
difference may be due to a combination of PK/PD factors. First, 
it is possible that the three drugs have different uptake and PK 
profile in the zebrafish. For example, the low LogKow of captopril 
(0.27) suggests that zebrafish may not take up this compound from 
the surrounding water as effectively as propranolol and losartan 
(LogKow 3.1 and 3.5, respectively). This implies that water test 
concentrations may not be the most appropriate unit of comparison 
and that internal concentrations should be used whenever possible 
to inform comparative evaluations. On the other side, it is plausible 
that drug-specific pharmacodynamics contributed to the observed 
difference in water effect concentrations because of the different 
role played by beta-adrenergic receptors and renin–angiotensin 
system in the mediation of cardiovascular functions. Finally, in 
addition to the evolutionary considerations discussed above, it 
cannot be excluded that the renin–angiotensin system of zebrafish 
at 7 dpf may not be fully mature from a molecular and functional 
perspective; however, to our knowledge, no data are currently 
available to evaluate the plausibility of this hypothesis.
CONCLUSIONS, LIMITATIONS, AND 
FUTURE PERSPECTIVES
Our meta-analysis revealed some striking similarities between 
zebrafish and mammalian responses to three common 
cardiovascular drugs: propranolol, losartan, and captopril. Our 
data suggest that, albeit based on data from a limited number of 
drugs, the cardiovascular effects of both beta-adrenergic receptor 
and angiotensin II type 1 receptor antagonism can be reliably 
demonstrated in larval zebrafish. In contrast, treatment to induce 
ACE inhibition led to results that were only partially in agreement 
with the known mammalian responses. This uncertainty would 
suggest that this specific mechanism of action should be considered 
outside the domain of applicability of the zebrafish model for drug 
testing, until more robust evidence becomes available.
As already demonstrated previously by Parker et al. (2014), the 
in vivo imaging of zebrafish larvae appears to be a highly valuable 
approach that enables the noninvasive detection of drug-induced 
integrated cardiovascular effects. Nonetheless, it is important to 
highlight certain shortcomings of our study that may have affected, 
in some cases, the degree of reliability of the overall results. The first 
and most obvious limitation is the relatively low statistical power of 
the experiments, carried out using six animals per treatment group. 
The selection of this design was driven both by previous experiments 
(Parker et al., 2014), by the practical aspects of the in vivo imaging 
process, and by the aim of generating a procedure suitable for 
higher-throughput testing. Of note, however, is that this limitation 
applies not only to our study but also to several papers from which 
we extracted the mammalian data used in our meta-analysis. As 
far as zebrafish tests are concerned, the data we generated can be 
used to set the statistical power of future experiments and achieve 
an optimal design (e.g., by increasing sample size in line with the 
objective of the experiment). In some cases, the sensitivity of the 
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experiment could be increased by testing a cardiovascular disease 
model or by employing genetically engineered zebrafish strains that 
express fluorescent tags in specific cells. The latter approach may 
offer a powerful multiscale perspective on drug action and facilitate 
the interpretation of apical phenotypic processes.
A second important limitation of our zebrafish test was the 
lack of data concerning the internal concentration of the drug in 
the animal. This missing piece of information prevents the full 
translation of PK/PD dynamics observed in zebrafish to other 
species. The routine quantification of drug internal concentrations 
in zebrafish larvae remains technically challenging (e.g., it is 
difficult to separate the larvae from the exposure medium while 
minimizing the risk of contaminations or leaching); it requires 
access to specialized analytical chemistry support and increases 
the overall cost of each experiment. There are examples where the 
authors successfully performed such analysis (e.g., Parker et al., 
2014), but, in general, those studies remain an exception rather 
than the rule. Previous studies have demonstrated the importance 
of internal exposure dynamics to interpret drug-mediated effects 
in adult fish (Margiotta-Casaluci et al., 2016). It is highly plausible 
that this aspect is also critically important when larval stages are 
used. Considering that the routine quantification of drug internal 
concentrations in zebrafish larvae may remain unrealistic for 
many laboratories, coordinated efforts aimed at developing PBPK 
model for the larval life stages may offer a good compromise that 
would enhance the translational value of the zebrafish model.
The key novel aspect of our work is application of a meta-
analysis approach for the quantitative assessment of preclinical 
model translational potential. This approach, combined with 
a suitable data visualization strategy, revealed patterns of 
response that would likely remain undetected by employing 
more traditional methods of qualitative comparative analysis, 
including the consideration of a few selected papers as a term of 
comparison, for example, the use of only statistically significant 
results (i.e., p < 0.05) to guide data interpretation, the employment 
of textual or table formats to express similarities and differences. The 
method we used in our study allowed us to zoom out from single 
studies in an unbiased manner and revealed a surprising overlap of 
effect magnitudes across species, as well as unexpected intraspecies 
discrepancies. It also provides a fully transparent platform to evaluate 
data reproducibility and, in turn, support decision-making. We 
propose that expanding the meta-analysis of interspecies responses 
to other target–phenotype combinations in the future will help to 
precisely define the domain of applicability of zebrafish and increase 
the confidence in its application. Achieving this goal may help to 
fully unlock the 3Rs potential of the zebrafish model, which may 
play a key role in the design of future testing strategies, representing 
an important and crucial bridge between high throughput in vitro 
and low throughput, high content mammalian in vivo testing.
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Comparative effect of bisoprolol and losartan in the treatment of essential 
hypertension. J. Res. Med. Sci. 17, 1027–1032. 
Keßler, M., Rottbauer, W., and Just, S. (2015). Recent progress in the use of 
zebrafish for novel cardiac drug discovery. Expert Opin. Drug Discov. 10, 1231–
1241. doi: 10.1517/17460441.2015.1078788
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., and Altman, D. (2010). 
Improving bioscience research reporting: the ARRIVE guidelines for reporting 
animal research. J. Pharmacol. Pharmacother. 1, 94–99. doi: 10.1371/journal.
pbio.1000412
Kimura, K., Tojo, A., Matsuoka, H., and Sugimoto, T. (1991). Renal arteriolar 
diameters in spontaneously hypertensive rats. vascular cast study. Hypertension 
18, 101–110. doi: 10.1161/01.HYP.18.1.101
Kitambi, S. S., McCulloch, K. J., Peterson, R. T., and Malicki, J. J. (2009). Small 
molecule screen for compounds that affect vascular development in the 
zebrafish retina. Mech. Dev. 126, 464–477. doi: 10.1016/j.mod.2009.01.002
Koike, H., Ito, K., Miyamoto, M., and Nishino, H. (1980). Effects of long-term 
blockade of angiotensin converting enzyme with captopril (SQ 14,225) on 
hemodynamics and circulating blood volume in SHR. Hypertension 2, 299–
303. doi: 10.1161/01.HYP.2.3.299
Konstam, M. A., Patten, R. D., Thomas, I., Ramahi, T., La Bresh, K., Goldman, S., 
et al. (2000). Effects of losartan and captopril on left ventricular volumes in 
elderly patients with heart failure: results of the ELITE ventricular function 
substudy. Am. Heart J. 139, 1081–1087. doi: 10.1067/mhj.2000.105302
Koprdova, R., Cebova, M., and Kristek, F. (2009). Long-term effect of losartan 
administration on blood pressure, heart and structure of coronary artery of 
young spontaneously hypertensive rats. Physiol. Res. 58, 327–335. 
Kuhn, F. E., Johnson, M. N., Gillis, R. A., Visner, M. S., and Schaer, G. L. (1990). 
Effect of cocaine on the coronary circulation and systemic hemodynamics in 
dogs. J. Am. Coll. Cardiol. 16, 1481–1491. doi: 10.1016/0735-1097(90)90396-7
Kumai, Y., Bernier, N. J., and Perry, S. F. (2014). Angiotensin-II promotes 
Na+ uptake in larval zebrafish, Danio rerio, in acidic and ion-poor water. 
J. Endocrinol. 220, 195–205. doi: 10.1530/JOE-13-0374
Ladage, D., Schwinger, R. H. G., and Brixius, K. (2013). Cardio-selective beta-
blocker: pharmacological evidence and their influence on exercise capacity. 
Cardiovasc. Ther. 31, 76–83. doi: 10.1111/j.1755-5922.2011.00306.x
Lambert, C. (1995). Mechanisms of angiotensin II chronotropic effect in 
anaesthetized dogs. Br. J. Pharmacol. 115, 795–800. doi: 10.1111/j.1476-
5381.1995.tb15003.x
Land, S., Park-Holohan, S. J., Smith, N. P., dos Remedios, C. G., Kentish, J. C., 
and Niederer, S. A. (2017). A model of cardiac contraction based on novel 
measurements of tension development in human cardiomyocytes. J. Mol. Cell 
Cardiol. 106, 68–83. doi: 10.1016/j.yjmcc.2017.03.008
Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., 
et al. (2011). How can we improve our understanding of cardiovascular safety 
liabilities to develop safer medicines? Br. J. Pharmacol. 163, 675–693. doi: 
10.1111/j.1476-5381.2011.01255.x
Leier, C. V., Bambach, D., Nelson, S., Hermiller, J. B., Huss, P., Magorien, R. D., 
et  al. (1983). Captopril in primary pulmonary hypertension. Circulation 67, 
155. doi: 10.1161/01.CIR.67.1.155
Leishman, D. J., Beck, T. W., Dybdal, N., Gallacher, D. J., Guth, B. D., Holbrook, M., 
et al. (2012). Best practice in the conduct of key nonclinical cardiovascular 
assessments in drug development: current recommendations from the 
safety pharmacology society. J. Pharmacol. Toxicol. Methods 65, 93–101. doi: 
10.1016/j.vascn.2011.08.006
Lester, R. M., and Olbertz, J. (2016). Early drug development: assessment of 
proarrhythmic risk and cardiovascular safety. Expert Rev. Clin. Pharmacol. 9, 
1611–1618. doi: 10.1080/17512433.2016.1245142
Leucht, S., Helfer, B., Gartlehner, G., and Davis, J. M. (2015). How effective are 
common medications: a perspective based on meta-analyses of major drugs. 
BMC Med. 13, 253. doi: 10.1186/s12916-015-0494-1
Le Winter, M. M., Crawford, M. H., Karliner, J. S., and O’Rourke, R. A. (1975). 
Effects of oral propranolol in normal subjects. Clin. Pharmacol. Ther. 17, 709–
712. doi: 10.1002/cpt1975176709
Lynch, J. J., Stump, G. L., Wallace, A. A., Painter, C. A., Thomas, J. M., Kusma, S. E., 
et al. (1999). EXP3174, the AII antagonist human metabolite of losartan, but not 
losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents 
the development of lethal ischemic ventricular arrhythmias in a canine model 
of recent myocardial infarction. J. Am. Coll. Cardiol. 34, 876–884. doi: 10.1016/
S0735-1097(99)00253-3
MacFadyen, R. J., Tree, M., Lever, A. F., and Reid, J. L. (1992). Effects of the 
angiotensin II receptor antagonist Losartan (DuP 753/MK 954) on arterial 
blood pressure, heart rate, plasma concentrations of angiotensin II and renin 
and the pressor response to infused angiotensin II in the salt-deplete dog. Clin. 
Sci. 83, 549–556. doi: 10.1042/cs0830549
MacRae, C. A., and Peterson, R. T. (2015). Zebrafish as tools for drug discovery. 
Nat. Rev. Drug Discov. 14, 721–731. doi: 10.1038/nrd4627
Margiotta-Casaluci, L., Owen, S. F., Huerta, B., Rodríguez-Mozaz, S., Kugathas, S., 
Barceló, D., et al. (2016). Internal exposure dynamics drive the adverse 
outcome pathways of synthetic glucocorticoids in fish. Sci. Rep. 6, 21978. doi: 
10.1038/srep21978
Marks, L., Borland, S., Philp, K., Ewart, L., Lainée, P., Skinner, M., et al. (2012). The 
role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation 
of drug candidate compounds. Toxicol. Appl. Pharmacol. 263, 171–183. doi: 
10.1016/j.taap.2012.06.007
Marshall, R. C., Wisenberg, G., Schelbert, H. R., and Henze, E. (1981). Effect of 
oral propranolol on rest, exercise and postexercise left ventricular performance 
in normal subjects and patients with coronary artery disease. Circulation 63, 
572–583. doi: 10.1161/01.CIR.63.3.572
Massie, B., Kramer, B. L., Topic, N., and Henderson, S. G. (1982). Hemodynamic 
and radionuclide effects of acute captopril therapy for heart failure: changes 
in left and right ventricular volumes and function at rest and during exercise. 
Circulation 65, 1374–1381. doi: 10.1161/01.CIR.65.7.1374
Matrougui, K., Lévy, B. I., and Henrion, D. (2000). Tissue angiotensin II and 
endothelin-1 modulate differently the response to flow in mesenteric resistance 
arteries of normotensive and spontaneously hypertensive rats. Br. J. Pharmacol. 
130, 521–526. doi: 10.1038/sj.bjp.0703371
McDonald, D. G., Tang, Y., and Boutilier, R. G. (1989). The role of β-adrenoreceptors 
in the recovery from exhaustive exercise of freshwater-adapted rainbow trout. 
J. Exp. Biol. 147, 471–491. 
McKenzie, D. J., Taylor, E. W., Bronzi, P., and Bolis, C. L. (1995). Aspects of 
cardioventilatory control in the adriatic sturgeon (Acipenser naccarii). Respir. 
Physiol. 100, 45–53. doi: 10.1016/0034-5687(94)00121-F
Miguel-Carrasco, J. L., Zambrano, S., Blanca, A. J., Mate, A., and Vázquez, C. M. 
(2010). Captopril reduces cardiac inflammatory markers in spontaneously 
hypertensive rats by inactivation of NF-kB. J. Inflamm. 7, 21. doi: 
10.1186/1476-9255-7-21
Milan, D. J., Jones, I. L., Ellinor, P. T., and MacRae, C. A. (2006). In vivo recording 
of adult zebrafish electrocardiogram and assessment of drug-induced QT 
prolongation. Am. J. Physiol. Heart Circ. Physiol. 291, 269. doi: 10.1152/
ajpheart.00960.2005
Inter-Species Effects of Cardiovascular DrugsMargiotta-Casaluci et al.
21 August 2019 | Volume 10 | Article 893Frontiers in Pharmacology | www.frontiersin.org
Milani-Nejad, N., and Janssen, P. M. L. (2014). Small and large animal models in 
cardiac contraction research: advantages and disadvantages. Pharmacol. Ther. 
141, 235–249. doi: 10.1016/j.pharmthera.2013.10.007
Mo, Y. H., Jaw, F. S., Wang, Y. C., Jeng, C. M., and Peng, S. F. (2011). Effects 
of propranolol on the left ventricular volume of normal subjects during 
CT coronary angiography. Korean J. Radiol. 12, 319–326. doi: 10.3348/
kjr.2011.12. 3.319
Morris, K. G., Higginbotham, M. B., Coleman, R. E., Shand, D. G., and Cobb, F. R. 
(1983). Comparison of high-dose and medium-dose propranolol in the relief of 
exercise-induced myocardial ischemia. Am. J. Cardiol. 52, 7–13. doi: 10.1016/ 
0002-9149(83)90060-7
Nishimura, H., and Ogawa, M. (1973). The renin–angiotensin system in fishes. 
Integr. Comp. Biol. 13, 823–838. doi: 10.1093/icb/13.3.823
Owen, S. F., Giltrow, E., Huggett, D. B., Hutchinson, T. H., Saye, J., Winter, M. 
J., et al. (2007). Comparative physiology, pharmacology and toxicology of 
β-blockers: mammals versus fish. Aquat. Toxicol. 82, 145–162. doi: 10.1016/j.
aquatox.2007.02.007
Parker, T., Libourel, P., Hetheridge, M. J., Cumming, R. I., Sutcliffe, T. P., 
Goonesinghe, A. C., et al. (2014). A multi-endpoint in vivo larval zebrafish 
(Danio rerio) model for the assessment of integrated cardiovascular function. J. 
Pharmacol. Toxicol. Methods 69, 30–38. doi: 10.1016/j.vascn.2013.10.002
Passini, E., Britton, O. J., Lu, H. R., Rohrbacher, J., Hermans, A. N., Gallacher, 
D. J., et al. (2017). Human in silico drug trials demonstrate higher accuracy 
than animal models in predicting clinical pro-arrhythmic cardiotoxicity. Front. 
Physiol. 8, 668. doi: 10.3389/fphys.2017.00668
Paterna, S., Parrinello, G., Scaglione, R., Costa, R., Bova, A., Palumbo, V., et al. 
(2000). Effect of long-term losartan administration on renal haemodynamics 
and function in hypertensive patients. Cardiovasc. Drugs Ther. 14, 529–532. 
doi: 10.1023/A:1007845324117
Payan, P., and Girard, J. P. (1977). Adrenergic receptors regulating patterns of 
blood flow through the gills of trout. Am. J. Physiol. 232, 18. doi: 10.1152/
ajpheart.1977.232.1.H18
Pfeffer, J. M., Pfeffer, M. A., and Braunwald, E. (1985). Influence of chronic 
captopril therapy on the infarcted left ventricle of the rat. Circ. Res. 57, 84. doi: 
10.1161/01.RES.57.1.84
Pfeffer, J. M., Pfeffer, M. A., Mirsky, I., and Braunwald, E. (1982). Regression of 
left ventricular hypertrophy and prevention of left ventricular dysfunction by 
captopril in the spontaneously hypertensive rat. Proc. Natl. Acad. Sci. U. S. A. 
79, 3310–3314. doi: 10.1073/pnas.79.10.3310
Port, S., Cobb, F. R., and Jones, R. H. (1980). Effects of propranolol on 
left ventricular function in normal men. Circulation 61, 358–366. doi: 
10.1161/01.CIR.61.2.358
Randall, D. J., and Stevens, E. D. (1967). The role of adrenergic receptors in 
cardiovascular changes associated with exercise in salmon. Comp. Biochem. 
Physiol. 21, 415–424. doi: 10.1016/0010-406X(67)90803-1
Raya, T. E., Lee, R. W., Westhoff, T., and Goldman, S. (1989). Captopril restores 
hemodynamic responsiveness to atrial natriuretic peptide in rats with heart 
failure. Circulation 80, 1886–1892. doi: 10.1161/01.CIR.80.6.1886
Rider, S. A., Christian, H. C., Mullins, L. J., Howarth, A. R., MacRae, C. A., 
and Mullins, J. J. (2017). Zebrafish mesonephric renin cells are functionally 
conserved and comprise two distinct morphological populations. Am. J. 
Physiol. Renal Physiol. 312, F790. doi: 10.1152/ajprenal.00608.2016
Rochette, L., Bralet, J., and Rochat, C. (1987). Effects of propranolol and tertatolol 
on cardiac output and regional blood flows in the rat. Drug Dev. Res. 10, 17–26. 
doi: 10.1002/ddr.430100104
Rozsa, Z., and Sonkodi, S. (1995). The effect of long-term oral captopril treatment 
on mesenteric blood flow in spontaneously hypertensive rats. Pharmacol. Res. 
32, 21–25. doi: 10.1016/S1043-6618(95)80004-2
Russell, M. J., Klemmer, A. M., and Olson, K. R. (2001). Angiotensin signaling and 
receptor types in teleost fish. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 
128, 41–51. doi: 10.1016/S1095-6433(00)00296-8
Saigal, S., Chawla, Y., and Dilawari, J. B. (1998). Assessment of effects of 
propranolol on portal hemodynamics in cirrhosis by duplex ultrasonography. 
Indian J. Gastroenterol. 17, 51–52. 
Satoh, S., Fujisawa, S., Tanaka, R., and Nakai, K. (1980). Effect of captopril, a 
converting enzyme inhibitor on renal vascular resistance in pentobarbital 
anesthetized dogs. Jpn. J. Pharmacol. 30, 515–519. doi: 10.1254/jjp.30.515
Schanzenbacher, P., and Liebau G. (1983) Effect of captopril on left ventricular 
dynamics in patients with chronic left ventricular volume overload. Klin 
Wochenschr. 61, 343-347. doi: 10.1007/BF01485025
Schiffrin, E. L., Park, J. B., Intengan, H. D., and Touyz, R. M. (2000). Correction of 
arterial structure and endothelial dysfunction in human essential hypertension 
by the angiotensin receptor antagonist losartan. Circulation 101, 1653–1659. 
doi: 10.1161/01.CIR.101.14.1653
Schreij, G., van Es, P. N., van Kroonenburgh, M. J. P. G., Kemerink, G. J., Heidendal, 
G. A. K., and de Leeuw, P. W. (1996). Baseline and postcaptopril renal blood 
flow measurements in hypertensives suspected of renal artery stenosis. J. Nucl. 
Med. 37, 1652. 
Schwerte, T., Prem, C., Mairösl, A., and Pelster, B. (2006). Development of the 
sympatho-vagal balance in the cardiovascular system in zebrafish (Danio rerio) 
characterized by power spectrum and classical signal analysis. J. Exp. Biol. 209, 
1093–1100. doi: 10.1242/jeb.02117
Schulz, M., Iwersen-Bergmann, S., Andresen, H., and Schmoldt, A. (2012). 
Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other 
xenobiotics. Crit. Care 16, R136. doi: 10.1186/cc11441
Sert, N. P., Bamsey, I., Bate, S. T., Berdoy, M., Clark, R. A., Cuthill, I., et al. (2017). 
The experimental design assistant. PLoS Biol. 15, e2003779. doi: 10.1371/
journal.pbio.2003779
Shannon, R. P., Friedrich, S., Mathier, M., and Knight, D. R. (1997). Effects of renin 
inhibition compared to angiotensin converting enzyme inhibition in conscious 
dogs with pacing-induced heart failure. Cardiovasc. Res. 34, 464–472. doi: 
10.1016/S0008-6363(97)00066-7
Siegl, P. K., Kivlighn, S. D., and Broten, T. P. (1995). Pharmacology of losartan, 
an angiotensin II receptor antagonist, in animal models of hypertension. 
J. Hypertens. Suppl. 13, 15–21. doi: 10.1097/00004872-199507001-00002
Skinner, M. H., Tan, D. X., Grossmann, M., Pyne, M. T., and Mahurin, R. K. (1996). 
Effects of captopril and propranolol on cognitive function and cerebral blood 
flow in aged hypertensive rats. J. Gerontol. A Biol. Sci. Med. Sci. 51, B454–B460. 
doi: 10.1093/gerona/51A.6.B454
Song, M. A., Dasgupta, C., and Zhang, L. (2015). Chronic losartan treatment 
up-regulates AT1R and increases the heart vulnerability to acute onset of 
ischemia and reperfusion injury in male rats. PLoS ONE 10, e0132712. doi: 
10.1371/journal.pone.0132712
Steele, S. L., Yang, X., Debiais-Thibaud, M., Schwerte, T., Pelster, B., Ekker, M., et al. 
(2011). In vivo and in vitro assessment of cardiac beta-adrenergic receptors in 
larval zebrafish (Danio rerio). J. Exp. Biol. 214, 1445–1457. doi: 10.1242/jeb.052803
Sturani, A., Chiarini, C., Degliesposti, E., Santoro, A., Zuccalà, A., and Zucchelli, 
P. (1982). Heart rate control in hypertensive patients treated by captopril. Br. J. 
Clin. Pharmacol. 14, 849–855. doi: 10.1111/j.1365-2125.1982.tb02048.x
Sudhir, K., MacGregor, J. S., Gupta, M., Barbant, S. D., Redberg, R., Yock, P. G., 
et al. (1993). Effect of selective angiotensin II receptor antagonism and 
angiotensin converting enzyme inhibition on the coronary vasculature in vivo. 
Intravascular two-dimensional and doppler ultrasound studies. Circulation 87, 
931–938. doi: 10.1161/01.CIR.87.3.931
Suzuki, J., Ohta, H., Hanada, K., Kawai, N., Ikeda, T., Nakao, M., et al. (2001). Acute 
effects of E-3174, a human active metabolite of losartan, on the cardiovascular 
system in tachycardia-induced canine heart failure. Hypertens. Res. 24, 65–74. 
doi: 10.1291/hypres.24.65
Tabo, M., Hara, T., Sone, S., Shishido, N., Kuramoto, S., Nakano, K., et al. (2008). 
Prediction of drug-induced QT interval prolongation in telemetered common 
marmosets. J. Toxicol. Sci. 33, 315–325. doi: 10.2131/jts.33.315
Van den Broek, S. A., de Graeff, P. A., Smit, A. J., Girbes, A. R., Journée, N., 
van Gilst, W. H., et al. (1995). Effects of spirapril and captopril on regional 
blood flow in chronic congestive heart failure: a comparison between a short- 
and a long-acting angiotensin-converting enzyme inhibitor. J. Cardiovasc. 
Pharmacol. 25, 105–112. doi: 10.1097/00005344-199501000-00017
Van Heeswijk, J. C. F., Vianen, G. J., and van den Thillart, G. E. E. J. M. (2006). The 
adrenergic control of hepatic glucose and FFA metabolism in rainbow trout 
(Oncorhynchus mykiss): increased sensitivity to adrenergic stimulation with 
fasting. Gen. Comp. Endocrinol. 145, 51–61. doi: 10.1016/j.ygcen.2005. 07.001
Vandenburg, M. J., Holly, J. M., Goodwin, F. J., Sharman, V. L., and Marsh, F. P. 
(1983). The effect of captopril and propranolol on the responses to posture 
and isometric exercise in patients with essential hypertension. Eur. J. Clin. 
Pharmacol. 25, 721–728. doi: 10.1007/BF00542509
Inter-Species Effects of Cardiovascular DrugsMargiotta-Casaluci et al.
22 August 2019 | Volume 10 | Article 893Frontiers in Pharmacology | www.frontiersin.org
Vargas, H. M., Bass, A. S., Koerner, J., Matis-Mitchell, S., Pugsley, M. K., Skinner, M., 
et al. (2015). Evaluation of drug-induced QT interval prolongation in animal 
and human studies: a literature review of concordance. Br. J. Pharmacol. 172, 
4002–4011. doi: 10.1111/bph.13207
Vatner, S. F., Vatner, D. E., and Homcy, C. J. (2000). Beta-adrenergic receptor 
signaling: an acute compensatory adjustment-inappropriate for the chronic 
stress of heart failure? Insights from Gsalpha overexpression and other 
genetically engineered animal models. Circ. Res. 86, 502–506. doi: 10.1161/01.
RES.86.5.502
Vauquelin, G., and Charlton, S. J. (2010). Long-lasting target binding and rebinding 
as mechanisms to prolong in vivo drug action. Br. J. Pharmacol. 161, 488–508. 
doi: 10.1111/j.1476-5381.2010.00936.x
Verbruggen, B., Gunnarsson, L., Kristiansson, E., Österlund, T., Owen, S. F., Snape, J. 
R., et al. (2017). ECOdrug: a database connecting drugs and conservation of their 
targets across species. Nucleic Acids Res. 46, D930–D936. doi: 10.1093/nar/gkx1024
Vigue, B., Ghaleh, B., Giudicelli, J., and Berdeaux, A. (1993). α1 and α2-adrenergic 
control of large and small coronary arteries during exercise in conscious dogs 
under β-blockade. Fundam. Clin. Pharmacol. 7, 513–521. doi: 10.1111/j.1472-
8206.1993.tb00255.x
Wang, D. H., and Prewitt, R. L. (1991). Longitudinal effect of captopril on aortic 
and arteriolar development in normotensive rats. Am. J. Physiol. 260, H1959–
H1965. doi: 10.1152/ajpheart.1991.260.6.H1959
Willems, B., Villeneuve, J. P., and Huet, P. M. (1986). Effect of propranolol on 
hepatic and systemic hemodynamics in dogs with chronic bile duct ligation. 
Hepatology 6, 92–97. doi: 10.1002/hep.1840060117
Winter, M. J., Redfern, W. S., Hayfield, A. J., Owen, S. F., Valentin, J., and 
Hutchinson, T. H. (2008). Validation of a larval zebrafish locomotor assay for 
assessing the seizure liability of early-stage development drugs. J. Pharmacol. 
Toxicol. Methods 57, 176–187. doi: 10.1016/j.vascn.2008.01.004
Wong, P. C., Zimmerman, B. G., Kraft, E., Kounenis, G., and Friedman, P. (1981). 
Pharmacological evaluation in conscious dogs of factors involved in the renal 
vasodilator effect of captopril. J. Pharmacol. Exp. Ther. 219, 646–650. 
Zain-Hamid, R., Ismail, Z., Mahendra Raj, S., Shuaib, I. L., and Mohsin, S. S. J. 
(2003). The effect of propranolol in malay patients with liver cirrhosis—a 
pharmacodynamic evaluation. Malays. J. Med. Sci. 10, 65–73. 
Zimmerman, B. G., Wong, P. C., Kounenis, G. K., and Kraft, E. J. (1982). No effect 
of intrarenal converting enzyme inhibition on canine renal blood flow. Am. J. 
Physiol. 243, H277–H283. doi: 10.1152/ajpheart.1982.243.2.H277
Conflict of Interest Statement: This work was cofunded by the AstraZeneca 
Global Safety, Health and Environment research program. MW was and SO is 
an employee of AstraZeneca, a biopharmaceutical company specialized in the 
discovery, development, manufacturing, and marketing of prescription medicines 
including propranolol used here. AstraZeneca provided support in the form of 
salaries for author SO (and for MW during the in vivo phase) and cofunded the 
BBSRC grant to MR-W, which supported LM-C.
Copyright © 2019 Margiotta-Casaluci, Owen, Rand-Weaver and Winter. This 
is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other 
forums is permitted, provided the original author(s) and the copyright owner(s) 
are credited and that the original publication in this journal is cited, in 
accordance with accepted academic practice. No use, distribution or reproduction 
is permitted which does not comply with these terms.
